WO1994003204A1 - Improving the body composition of fish via the administration of porcine somatotropin (pst) - Google Patents
Improving the body composition of fish via the administration of porcine somatotropin (pst) Download PDFInfo
- Publication number
- WO1994003204A1 WO1994003204A1 PCT/US1993/007498 US9307498W WO9403204A1 WO 1994003204 A1 WO1994003204 A1 WO 1994003204A1 US 9307498 W US9307498 W US 9307498W WO 9403204 A1 WO9403204 A1 WO 9403204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fish
- pst
- porcine somatotropin
- administered
- administration
- Prior art date
Links
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 43
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 26
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title description 17
- 230000001965 increasing effect Effects 0.000 claims abstract description 21
- 230000003247 decreasing effect Effects 0.000 claims abstract description 12
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 20
- 230000012010 growth Effects 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 241000277331 Salmonidae Species 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 235000019688 fish Nutrition 0.000 description 33
- 230000000694 effects Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 208000021017 Weight Gain Diseases 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241000252498 Ictalurus punctatus Species 0.000 description 2
- 241001280377 Oncorhynchus tshawytscha Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000044162 human IGF1 Human genes 0.000 description 2
- 235000020997 lean meat Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000277334 Oncorhynchus Species 0.000 description 1
- 241000277338 Oncorhynchus kisutch Species 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241000277263 Salmo Species 0.000 description 1
- 241000277289 Salmo salar Species 0.000 description 1
- 241000277284 Salvelinus fontinalis Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 210000000006 pectoral fin Anatomy 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/184—Hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/20—Shaping or working-up of animal feeding-stuffs by moulding, e.g. making cakes or briquettes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/25—Shaping or working-up of animal feeding-stuffs by extrusion
Definitions
- the present invention relates to methods for obtaining improvements to the body composition of fish. More particularly, the present invention provides methods for increasing lean (protein) mass, increasing moisture content and decreasing body fat mass of fish via the administration of porcine somatotropin.
- Porcine somatotropin is a well-characterized polypeptide hormone synthesized in and secreted from the anterior pituitary.
- pST derived from porcine pituitary gland is available from commercial sources (Sigma Chemical Co., St. Louis, Mo., U.S.A.).
- pST- ⁇ 7 A particularly preferred pST-like polypeptide, pST- ⁇ 7, is described in published European Patent Application No. 104,920 Al (Biogen N.V., published April 4, 1984). This same polypeptide is referred to as ⁇ 7pGH in Biogen's U.S. patent no. 4,766,224, the disclosure of which is incorporated by reference herein. From the foregoing, it is apparent that, prior to the present invention, no clear conclusions could be drawn regarding the effects of any particular heterologous somatotropin on fish. While some researchers reported overall weight and length gains, as least one group (Wilson et al.) reported increased body fat and decreased protein mass in treated fish.
- one of the objects of the present invention is to provide a method for enhancing the growth of fish and, specifically, for increasing the lean (protein) mass and decreasing the body fat content.
- the present invention provides a method for increasing the lean meat mass and decreasing the body fat mass of fish.
- the method comprises administering to a fish an amount of porcine somatotropin effective to achieve the same.
- the porcine somatotropin preferably is administered parenterally.
- the recombinant pST-like polypeptide pST- ⁇ 7 is administered. The administration of this polypeptide, as described in detail below, is seen to provide significant increases in lean mass, and significant decreases in body fat composition, when administered to fish.
- Figure 1 is a plot of trout body weight gain versus time for a study conducted according to the present invention.
- porcine somatotropin is administered on a periodic basis to fish.
- overall body weight gains and improvements in feed efficiency are attained.
- the improved body composition attributes include increased lean mass, decreased fat mass and increased moisture content.
- pST is available both as a natural product, derived from porcine tissues, as well as a recombinant product. In view of the substantial costs associated with obtaining pST from animal tissues, recombinantly produced pST and its structurally related derivatives and analogs are preferred.
- a particularly preferred recombinant, pST-like polypeptide is pST- ⁇ 7.
- This polypeptide has an amino acid sequence similar to that of native pST, but is missing the first 7 amino acid residues and includes an f-Met residue.
- pST- ⁇ 7 and recombinant vectors for its expression in, for example, E. coli are described in EP 104,920 which was mentioned earlier and is incorporated by reference herein.
- the pST may be administered to the fish in a variety of manners, including orally, parenterally, via an implanted dosage form or via an implanted osmotic pump. When orally administered, pST can be incorporated into a fish food preparation.
- pST for injection will be mixed with any of the known pharmaceutical carriers or vehicles which are suitable for use in the administration of pharmaceutical preparations to fish.
- implantable dosage forms of somatotropins, including pST are well known.
- the amount of pST which is administered to the fish is defined as an amount effective to bring about the desired body composition changes - increased lean (protein) mass, decreased body fat mass and increased moisture content.
- the protein content of the fish will be increased by at least about 1% (by weight) over a 12-week growth period, while the fat content of the fish will be decreased by at least about 1% over the same period.
- One mode of administration of pST in accordance with the present invention is based on periodic administration via parenteral injection.
- a pST dosage consisting of, for example, about 1 to about 15 ⁇ g per gram of body weight, preferably from about 5 to about 10 ⁇ g/g, administered parenterally at 7 or 14 days intervals, has been found to provide significant (p ⁇ 0.05) alterations to moisture, fat and protein content.
- Other modes of administration will be apparent to the ordinarily skilled scientist.
- a 3/32" pellet was fed for the first two weeks followed by a 50:50 mixture of the 3/32 and 1/8" pellet for a week, then the 1/8" pellet for the remainder of the trial.
- the fish were allowed two weeks to adapt to the environment before initiation of the study.
- the treatments consisted of pST ( ⁇ 7pGH as described in U.S. Patent No. 4,766,224) administered at 14-day intervals at doses of 0, 5 or 10 ⁇ g/g body weight and at 7-day intervals at doses of 5 ⁇ g/g body weight.
- Lyophilized pST was dissolved in an aqueous diluent (0.2 M tris, 2mM EDTA and 0.15% BRIJ-3) to which was added streptomycin sulfate (lOO ⁇ g/ml), Penicillin G (100 IU/ml), and amphotericin B (0.25 ⁇ g/ml) for prophylaxis.
- Administration volume was 1 ⁇ l/g body weight.
- Trout were netted from the troughs, anesthetized in methane tricaine sulfonate (100 ppm), blotted with moist absorbent towels, weighted to the nearest 0.1 g, and injected to the nearest ⁇ l into the body cavity along the ventral body wall behind either pectoral fin with Hamilton syringes and 27-gauge needles.
- the trout were placed in an aerated recovery bath containing 5 ppt NaCl and 5 ppm Chloramine-T for disease prophylaxis. After recovery, the fish were returned to the appropriate trough. Ten fish per tank were selected for body composition analysis at the start of the study.
- the data collected and/or calculated included initial weight, final weight, average daily gain, feed conversion efficiency, chemical analysis of body composition and protein and fat accretion rates.
- the data were analyzed by analysis of variance with planned mean comparisons (SAS ® , 1989).
- Trout performance during the growth period is presented in Table 2 with weight gain illustrated in Figure 1.
- Initial trout weight was similar among the treatment groups.
- Final weight and average daily gain were significantly (p ⁇ 0.01) greater with pST administration as compared to the control groups.
- Administration of 5 or 10 ⁇ g/g body weight at 14-day intervals resulted in a 15% and 8% improvement in average daily gain, respectively, as compared to the control.
- a 41% improvement in average daily gain was observed when 5 ⁇ g/g pST were administered on a weekly basis, as compared to the control.
- Even though there was no significant difference between the performance of the two control groups performance appears poorer with the fish being handled weekly as compared to biweekly. This probably results from the increase in stress due to more frequent handling.
- Feed conversion efficiency was significantly (P ⁇ 0.01) improved in trout treated with pST as compared to the controls.
- Administration of pST on a biweekly basis resulted in an 11% and 8% improvement in feed efficiency for the 5 and 10 ⁇ g/g treatments, respectively, as compared to the control.
- pST was administered on a weekly basis, a 20% improvement in feed efficiency gain was observed as compared to the control. This level of improvement is considerably greater than that previously reported for other somatotropins and types of fish.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
Recombinant porcine somatotropin (rpST) is administered to fish and provides increased protein content, increased moisture content and decreased body fat mass. Thus, the use of rpST appears effective in improving the productivity of the fisheries industry.
Description
IMPROVING THE BODY COMPOSITION OF FISH VIA THE ADMINISTRATION OF PORCINE SOMATOTROPIN (PST)
Background of the Invention
1. Technical Field
The present invention relates to methods for obtaining improvements to the body composition of fish. More particularly, the present invention provides methods for increasing lean (protein) mass, increasing moisture content and decreasing body fat mass of fish via the administration of porcine somatotropin.
2. Background Art Numerous studies have demonstrated the efficacy of various somatotropins for generally enhancing weight gain in fish. Recombinant bovine, human, as well as a bovine analog of somatotropin have been shown to be effective in inducing weight gain in various fish, such as trout, salmon, and catfish. Down et al . , in Growth Acceleration of Seawater-Adapted Female Chinook Salmon . . ., J. World Aqua. Soc. 20:4, 181-187 (1989) demonstrated that recombinant bovine growth hormone (rbGH), administered in a continuous fashion by osmotic pumps, can accelerate the growth of sub-adult chinook salmon. Growth was measured as increases in length and weight only - no body composition analyses were reported.
In an earlier article, Down et al. showed that rbGh and an analog of rbGH ( "21K-rbGH" ) caused increases in weight and length, but no change in moisture content, of coho salmon to which the hormones were administered. Changes in body composition (that is, percent fat or lean meat mass) were not reported. Down et al. did observe, however, that the "condition factor" of the treated fish (condition factor is a function of weight ÷ length) was actually reduced in comparison to untreated fish over a portion of the treatment period. The authors attributed this observation to effects of somatotropin on bone growth. See Down et al. , A Potent Analog of Recombinant Bovine Somatotropin . . ., Can. J. Fish. Aquat. Sci. 46, 178- 183 (1989).
R. Wilson et al., in Effect of Recombinant Bovine Growth Hormone Administration on Growth and Body Composition of Channel Catfish, Aquaculture 73, 229- 236 (1988), report that the administration of rbGH to fingerling channel catfish results in an increase in weight gain, but that the increase is due to increased fat deposition. Body composition analysis showed both an increase in fat deposition and a decrease in body protein content of fish receiving rbGH when compared to the controls.
Skyrud et al., Effects of Recombinant Human Growth Hormone and Insulin-like Growth Factor 1 on Body Growth and Blood Metabolites in Brook Trout ( Salvelinus fontinalis), Gen. and Comp. Endocrin. 75, 247-255 (1989), report that the administration of human growth hormone resulted in overall increased growth (weight, length and liver weight) of trout. Human IGF-1, another hormone known to stimulate growth in mammals, had no growth-stimulating effect on trout, however. In
higher doses, IGF-1 actually retarded growth and increased mortality.
In Komourdijan et al. , The Effect of Porcine Somatotropin on Growth, and Survival in Seawater of Atlantic Salmon ( Salmo salar) Parr, Can. J. Zool. 54, 531-535 (1976), the authors report that the administration of porcine somatotropin results in increased length and weight, and decreased condition factor, over non-treated controls. Again, no body composition data were presented by the authors.
Porcine somatotropin (pST) is a well-characterized polypeptide hormone synthesized in and secreted from the anterior pituitary. pST derived from porcine pituitary gland is available from commercial sources (Sigma Chemical Co., St. Louis, Mo., U.S.A.).
Recombinant pST and various bio-active fragments and analogs thereof also have been described in the literature. A particularly preferred pST-like polypeptide, pST-Δ7, is described in published European Patent Application No. 104,920 Al (Biogen N.V., published April 4, 1984). This same polypeptide is referred to as Δ7pGH in Biogen's U.S. patent no. 4,766,224, the disclosure of which is incorporated by reference herein. From the foregoing, it is apparent that, prior to the present invention, no clear conclusions could be drawn regarding the effects of any particular heterologous somatotropin on fish. While some researchers reported overall weight and length gains, as least one group (Wilson et al.) reported increased body fat and decreased protein mass in treated fish. Thus, improvements in fish propagation techniques, and, specifically, in lean mass enhancement and fat reduction, remain a goal of the fisheries industry.
Accordingly, one of the objects of the present invention is to provide a method for enhancing the growth of fish and, specifically, for increasing the lean (protein) mass and decreasing the body fat content.
Summary of the Invention
The foregoing and other objects are achieved by the present invention which, in one aspect, provides a method for increasing the lean meat mass and decreasing the body fat mass of fish. The method comprises administering to a fish an amount of porcine somatotropin effective to achieve the same. The porcine somatotropin preferably is administered parenterally. In the most preferred aspects of the invention, the recombinant pST-like polypeptide pST-Δ7 is administered. The administration of this polypeptide, as described in detail below, is seen to provide significant increases in lean mass, and significant decreases in body fat composition, when administered to fish.
Brief Description of the Drawing
Figure 1 is a plot of trout body weight gain versus time for a study conducted according to the present invention.
Detailed Description of the Preferred Embodiments
In accordance with the present invention, porcine somatotropin is administered on a periodic basis to fish. Advantageously, overall body weight gains and improvements in feed efficiency are attained. More importantly, however, it has now been discovered that the administration of pST to fish provides marked
improvements in body composition as well. The improved body composition attributes include increased lean mass, decreased fat mass and increased moisture content. As mentioned briefly above, pST is available both as a natural product, derived from porcine tissues, as well as a recombinant product. In view of the substantial costs associated with obtaining pST from animal tissues, recombinantly produced pST and its structurally related derivatives and analogs are preferred.
A particularly preferred recombinant, pST-like polypeptide is pST-Δ7. This polypeptide has an amino acid sequence similar to that of native pST, but is missing the first 7 amino acid residues and includes an f-Met residue. pST-Δ7 and recombinant vectors for its expression in, for example, E. coli are described in EP 104,920 which was mentioned earlier and is incorporated by reference herein. The pST may be administered to the fish in a variety of manners, including orally, parenterally, via an implanted dosage form or via an implanted osmotic pump. When orally administered, pST can be incorporated into a fish food preparation. pST for injection will be mixed with any of the known pharmaceutical carriers or vehicles which are suitable for use in the administration of pharmaceutical preparations to fish. Similarly, implantable dosage forms of somatotropins, including pST, are well known. In general, the amount of pST which is administered to the fish is defined as an amount effective to bring about the desired body composition changes - increased lean (protein) mass, decreased body fat mass and increased moisture content. At dosages
sufficient to bring about these effects, other beneficial effects such as generally increased body weight and size, and enhanced feed efficiency, will be realized as well. Advantageously the protein content of the fish will be increased by at least about 1% (by weight) over a 12-week growth period, while the fat content of the fish will be decreased by at least about 1% over the same period.
One mode of administration of pST in accordance with the present invention is based on periodic administration via parenteral injection. A pST dosage consisting of, for example, about 1 to about 15 μg per gram of body weight, preferably from about 5 to about 10 μg/g, administered parenterally at 7 or 14 days intervals, has been found to provide significant (p<0.05) alterations to moisture, fat and protein content. Other modes of administration will be apparent to the ordinarily skilled scientist.
In one series of experiments which demonstrate the efficacy of the invention, a total of 400 rainbow trout ( Oncorhynchus mykiεε) within one standard deviation of the initial population weight were randomly selected and equally distributed to 20 constantly aerated tanks (225 cm long X 42.5 cm deep X 25 cm wide). Water mean temperature was maintained with spring water at 15°C. A 12 hour light - 12 hour dark photoperiod was maintained. The trout were fed Rangen Salmon Grower pellets (Table 1) except 24 h before handling. Feed offered was increased on a daily basis to insure that feed was not growth limiting. A 3/32" pellet was fed for the first two weeks followed by a 50:50 mixture of the 3/32 and 1/8" pellet for a week, then the 1/8" pellet for the remainder of the trial. The fish were
allowed two weeks to adapt to the environment before initiation of the study.
Table 1 Composition of Rangen Salmon Grower Feed Component (%) Pellet (1/8") Pellet (3/32")
Protein 50.4 48.9
Fat 15.7 16.3
Moisture 8.02 8.49
Ash 9.91 8.92 Crude fiber 0.73 1.26
The treatments consisted of pST (Δ7pGH as described in U.S. Patent No. 4,766,224) administered at 14-day intervals at doses of 0, 5 or 10 μg/g body weight and at 7-day intervals at doses of 5 μg/g body weight. Lyophilized pST was dissolved in an aqueous diluent (0.2 M tris, 2mM EDTA and 0.15% BRIJ-3) to which was added streptomycin sulfate (lOOμg/ml), Penicillin G (100 IU/ml), and amphotericin B (0.25 μg/ml) for prophylaxis. Administration volume was 1 μl/g body weight.
Trout were netted from the troughs, anesthetized in methane tricaine sulfonate (100 ppm), blotted with moist absorbent towels, weighted to the nearest 0.1 g, and injected to the nearest μl into the body cavity along the ventral body wall behind either pectoral fin with Hamilton syringes and 27-gauge needles. Immediately after the injection, the trout were placed in an aerated recovery bath containing 5 ppt NaCl and 5 ppm Chloramine-T for disease prophylaxis. After recovery, the fish were returned to the appropriate trough.
Ten fish per tank were selected for body composition analysis at the start of the study. At the end of the 12-week study, five randomly selected fish per tank were selected for body composition analysis. Feed was withheld from these fish for 48 hours before sacrifice. Whole carcasses were ground and sub-sampled for analysis. The samples were analyzed for fat by ether extraction, for total moisture content by oven drying at 100°C and for lean mass (protein) content by Kjedahl analysis (AOAC, 1980).
The study was conducted as a randomized block design. The data collected and/or calculated included initial weight, final weight, average daily gain, feed conversion efficiency, chemical analysis of body composition and protein and fat accretion rates. The data were analyzed by analysis of variance with planned mean comparisons (SAS®, 1989).
Trout performance during the growth period is presented in Table 2 with weight gain illustrated in Figure 1. Initial trout weight was similar among the treatment groups. Final weight and average daily gain were significantly (p<0.01) greater with pST administration as compared to the control groups. Administration of 5 or 10 μg/g body weight at 14-day intervals resulted in a 15% and 8% improvement in average daily gain, respectively, as compared to the control. A 41% improvement in average daily gain was observed when 5 μg/g pST were administered on a weekly basis, as compared to the control. Even though there was no significant difference between the performance of the two control groups, performance appears poorer with the fish being handled weekly as compared to biweekly. This probably results from the increase in stress due to more frequent handling.
Feed conversion efficiency was significantly (P<0.01) improved in trout treated with pST as compared to the controls. Administration of pST on a biweekly basis resulted in an 11% and 8% improvement in feed efficiency for the 5 and 10 μg/g treatments, respectively, as compared to the control. When pST was administered on a weekly basis, a 20% improvement in feed efficiency gain was observed as compared to the control. This level of improvement is considerably greater than that previously reported for other somatotropins and types of fish.
Whole body composition as well as fat and protein accretion rates of the trout at the completion of the trial are presented in Table 3. Administration of pST to trout significantly (P<0.05) altered the body content of moisture, fat and protein. Both moisture and protein were increased 5% for both the 5 and 10 μg/g biweekly treatments as compared to the controls. However, the 5μg/g weekly treatment only increased protein content 1% as compared to the control. Protein accretion was significantly (P<.01) enhanced by pST administration as compared to the controls. Protein accretion was increased by 21 and 13% for the fish treated biweekly with 5 or 10 μg/g, respectively, as compared to the controls. Treatment of trout with 5 μg/g weekly resulted in a 42% increase in protein accretion as compared to control fish. The fat content was decreased 7 and 11% for the 5 and 10 μg/g biweekly treated fish, respectively, as compared to the controls. When the pST was administered at 5μg/g weekly, a 13% reduction in fat occurred as compared to the controls. Fat accretion was not significantly (p>0.10) affected by treatment. This is believed to be the first demonstration of enhanced body protein
accretion and decreased percent body fat content of fish as a result of somatotropin administration.
Table 2
Effect of pST Administration on the Growth Performance of Rainbow Trout
0 pST/14 vs 0 pST/7 NS No pST vs pST NS
0 pST/7 vs 5 pST/7 NS
Table 3
Effect of pST Administration on the Whole Bod Com osition of Rainbow Trout
CV 1.4 9.1 1.8 11.6 15.2
Contrasts P values
0pST/14 vs 0 pST/7 NS NS .0319 .0009 NS No pST vs pST .0055 .0150 .0168 NS NS 0 pST/7 vs 5 pST/7 .0452 .0449 NS ,0384 NS 0pST/14 vs 5 pST/14 NS NS .0110 ,0012 NS
Although the present invention has been described in connection with certain preferred embodiments and specific examples, it is not so limited. Variations with the scope of the claims will be readily apparent.
Claims
1. A method for increasing the protein content and protein accretion or decreasing the fat content and fat accretion of fish, comprising administering to a fish an amount of porcine somatotropin effective to achieve the same.
2. A method according to claim 1 wherein the porcine somatotropin is administered orally or parenterally in an amount of from about 1 to about 15 μg per gram of body weight.
3. A method according to claim 1 wherein the porcine somatotropin is administered via a subcutaneous implant so as to provide an effective dosage of from about 0.001 to about 0.1 μg per gram of body weight per day.
4. A method according to claim 1 wherein the body fat content of the fish is decreased, over a 12-week growth period, by at least about 1% by weight compared to untreated fish.
5. A method according to claim 1 wherein the protein content of the fish is increased, over a 12-week growth period, by at least about 1% by weight compared to untreated fish.
6. A method according to claim 1 wherein the porcine somatotropin is a recombinant porcine somatotropin.
7. A method according to claim 1 wherein the porcine somatotropin is Δ7pST.
8. A method according to claim 4 wherein the porcine somatotropin is Δ7pST.
9. A method according to claim 5 wherein the porcine somatotropin is Δ7pST.
10. A method according to claim 1 wherein the porcine somatotropin is administered to trout.
11. A method according to claim 1 wherein the porcine somatotropin is administered to the fish once every 7 days.
12. A method according to claim 1 wherein the porcine somatotropin is administered to the fish once every 14 days.
13. A method according to claim 11 wherein the porcine somatotropin is administered by injection in an amount of from about 5 to about 10 μg/g.
14. A method according to claim 12 wherein the porcine somatotropin is administered by injection in an amount of from about 5 to about 10 μg/g.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48053/93A AU4805393A (en) | 1992-08-07 | 1993-08-09 | Improving the body composition of fish via the administration of porcine somatotropin (pst) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89450292A | 1992-08-07 | 1992-08-07 | |
US07/894,502 | 1992-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994003204A1 true WO1994003204A1 (en) | 1994-02-17 |
Family
ID=25403166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/007498 WO1994003204A1 (en) | 1992-08-07 | 1993-08-09 | Improving the body composition of fish via the administration of porcine somatotropin (pst) |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4805393A (en) |
WO (1) | WO1994003204A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0104920A1 (en) * | 1982-09-27 | 1984-04-04 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing swing growth hormone-like polypeptides |
EP0277043A2 (en) * | 1987-01-30 | 1988-08-03 | IMCERA Group Inc. | Method for recovering somatotropins from dilute aqueous solution |
EP0362999A2 (en) * | 1988-08-24 | 1990-04-11 | Fidelity Food Technologies Pty. Ltd. | Improved carcass quality |
EP0488279A2 (en) * | 1990-11-30 | 1992-06-03 | American Cyanamid Company | Somatotropins with alterations in the alpha-helix 3 region, alpha-helix 2 region combinations thereof, and in combination with other mutations |
-
1993
- 1993-08-09 WO PCT/US1993/007498 patent/WO1994003204A1/en active Application Filing
- 1993-08-09 AU AU48053/93A patent/AU4805393A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0104920A1 (en) * | 1982-09-27 | 1984-04-04 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing swing growth hormone-like polypeptides |
EP0277043A2 (en) * | 1987-01-30 | 1988-08-03 | IMCERA Group Inc. | Method for recovering somatotropins from dilute aqueous solution |
EP0362999A2 (en) * | 1988-08-24 | 1990-04-11 | Fidelity Food Technologies Pty. Ltd. | Improved carcass quality |
EP0488279A2 (en) * | 1990-11-30 | 1992-06-03 | American Cyanamid Company | Somatotropins with alterations in the alpha-helix 3 region, alpha-helix 2 region combinations thereof, and in combination with other mutations |
Non-Patent Citations (2)
Title |
---|
FILE SERVER STN KARLSRUHE,FILE BIOSIS ABSTRACT NO.80:134138 & BIOLOGICAL ABSTRACTS 69:9134 & PAK.J.ZOOL. 10(2).1978 (RECD.1979).119-1 * |
FILE SERVER STN KARLSRUHE,FILE BIOSIS ABSTRACT NO.92:94599 & BIOLOGICAL ABSTRACTS 93:51149 & AQUAT.LIVING RESOURC.4(3).1991.155-160 * |
Also Published As
Publication number | Publication date |
---|---|
AU4805393A (en) | 1994-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Donaldson et al. | Hormonal enhancement of growth | |
Sokolowska et al. | Induction of ovulation in goldfish, Carassius auratus, by pimozide and analogues of LH-RH | |
Breton et al. | Effects of acute versus sustained administration of GnRHa on GtH release and ovulation in the rainbow trout, Oncorhynchus mykiss | |
EP0201219B1 (en) | Growth-promoting compositions | |
US5036045A (en) | Method for increasing growth hormone secretion | |
EP0289186A2 (en) | Process for increasing the growth rate and enhancing the feed efficiency of meat producing livestock | |
KR19990021938A (en) | Chimeric Fatty-Pro-GIRF Analogues with Improved Biological Efficacy | |
Marte et al. | Induced spawning of maturing milkfish (Chanos chanos Forsskal) with gonadotropin-releasing hormone (GnRH) analogues administered in various ways | |
US4837202A (en) | Method for stimulating the immune system | |
IE912545A1 (en) | Stabilized somatotropin for parenteral administration | |
Matty | Nutrition, hormones and growth | |
Crim | Methods for acute and chronic hormone administration in fish | |
US6194384B1 (en) | Long-acting galenical formulation for GRF peptides | |
US5686413A (en) | Ractopamine and growth hormone combinations | |
Ramos | Luteinizing hormone-releasing hormone analogue (LH-RHa) induces precocious ovulation in common sole (Solea solea L.) | |
Billard et al. | Stimulation of gonadotropin secretion and spermiation in carp by pimozide-LRH-A treatment: effects of dose and time of day | |
Ballard et al. | Modification of animal growth with growth hormone and insulin-like growth factors | |
WO1994003204A1 (en) | Improving the body composition of fish via the administration of porcine somatotropin (pst) | |
Lubis et al. | Enrichment of recombinant growth hormone in diet containing different levels of protein enhanced growth and meat quality of striped catfish (Pangasionodon hypophthalmus) | |
US5017560A (en) | Poultry growth promotion | |
KR0129755B1 (en) | Phenetholamine and growth hormone combinations | |
NZ205742A (en) | Promoting growth of animals by administering somatomedin | |
Breton et al. | Effects of synthetic LH-RH and analog on plasma gonadotropin levels and maturational response to 17α-hydroxy-20β-dihydroprogesterone | |
US5122513A (en) | Fish growth using bovine placental lactogen | |
US5028591A (en) | Method for stimulating the immune system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD SK UA VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |